Neurobiological Technologies Stock Short Ratio

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Based on the latest financial disclosure, Neurobiological Technologies has a Short Ratio of 0.09 times. This is 97.69% lower than that of the Biotechnology sector and 98.79% lower than that of the Health Care industry. The short ratio for all United States stocks is 97.75% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Neurobiological Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobiological Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobiological Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.